Arcturus Therapeutics Advances Phase 2 Studies for ARCT-032 and ARCT-810 in Treating Cystic Fibrosis and Urea Cycle Disorder
Monday, 1 July 2024, 20:59
Overview
Arcturus Therapeutics continues to push forward with its promising treatments for cystic fibrosis and urea cycle disorder.
Main Points
- Advancement in phase 2 study for ARCT-032
- Expansion of program for ARCT-810
- Potential therapeutic benefits for cystic fibrosis and urea cycle disorder
Conclusion: Arcturus's ongoing efforts demonstrate a commitment to advancing medical solutions for serious genetic conditions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.